Equity Purchase. Executive shall be eligible to purchase an initial amount of Equity in Niles LLC for payment as agreed upon between Niles LLC and the Executive.
Equity Purchase. (1) Party B hereby irrevocably grants to Party A the right to purchase at any time, or designate any third party to purchase, all or part of Party B’s equity interest in Party C, provided permitted under Chinese laws and regulations. Apart from Party A or any third party designated by Party A, no other person shall have the right to purchase such equity interest. Party C agrees to such grant by Party B to Party A. For the purpose of this Agreement, a “third party” or a “person” may be a natural person, company, partnership, enterprise, trust agency or other non-corporate entity.
(2) To the extent permitted under Chinese laws and regulations, Party A shall exercise such right to purchase the equity interest by written notice to Party B specifying the amount of equity to be purchased;
(3) Unless otherwise required under Chinese laws and regulations, the transaction price for the equity transfer hereunder shall be the lowest price permitted under Chinese law;
(4) All the money obtained by Party B from transfer of its interest in Party C hereunder shall be used to satisfy Party B’s payment obligations under the Loan Agreement.
Equity Purchase. On the Execution Date, Licensee and Company shall execute (a) a Stock Purchase Agreement, pursuant to which (i) Licensee will purchase 3,000,000 shares (the “Purchased Shares”) of common stock, par value $0.01 per share, of Company (“Common Stock”) for an aggregate purchase price of $14,691,930 and (ii) Company will execute and deliver to, and in favor of, Licensee, a warrant on customary terms reasonably acceptable to Licensee (the “Warrant”), pursuant to which Licensee will have the right, until February 10, 2020, to purchase up to 8,655,804 shares (the “Warrant Shares”) of Common Stock at an exercise price of $4.90 per share (in each case, subject to adjustment in accordance with the terms of the Warrant), and (b) a Registration Rights Agreement, pursuant to which Company will agree to register the Purchased Shares and the Warrant Shares.
Equity Purchase. ICN and Schering-Plough Corporation are contemporaneously with this Agreement entering into the Stock Purchase Agreement.
Equity Purchase. 19 12. CONFIDENTIALITY.........................................................................................19
Equity Purchase. Pursuant to the Stock Purchase Agreement, PathoGenesis shall purchase Two Million Five Hundred Thousand Dollars ($2,500,000) of Series E Preferred Stock of AeroGen, at a purchase price of $2.60 per share.
Equity Purchase. Concurrent with the execution of this Agreement, Biogen Idec shall purchase thirty million U.S. dollars ($30,000,000) of AVEO’s Series E Convertible Preferred Stock, $.001 par value per share, at a purchase price of $4.00 per share, pursuant to, and in accordance with the terms of, the form of Stock Purchase Agreement attached to this Agreement as Exhibit C.
Equity Purchase. Simultaneous with the execution of this Agreement Cephalon and Angioblast have entered into that certain Stock Purchase Agreement dated as of even date herewith by and among Angioblast, Cephalon and the individuals and entities listed on the exhibits thereto pursuant to which Cephalon shall purchase certain currently outstanding equity securities of Angioblast in accordance with the terms of such agreement.
Equity Purchase. Upon execution of this Agreement, ImClone shall purchase 1,000,000 shares (on a pre-split basis and subject to adjustment) of Common Stock of CombiChem at a per share purchase price equal to $2.00 per share for an aggregate purchase price of U.S. $2 million, pursuant to the terms of that certain Common Stock Purchase Agreement, dated as of the Effective Date, by and between CombiChem and ImClone (together with all ancillary agreements thereto, the "Stock Purchase Agreement"). In the event that CombiChem closes an initial public offering of its common stock at a sales price per share to the public (the "IPO Price") which is less than $2.50 per share (on a pre-split basis), then, upon the closing of such initial public offering, CombiChem shall issue to ImClone, without further consideration other than the purchase price paid by ImClone pursuant to the Stock Purchase Agreement, such additional number of shares of CombiChem common stock equal to: 2,000,000 -------------- -1,000,000 Adjusted Price wherein the "Adjusted Price" = the IPO Price X .80 if the IPO Price is less than $2.50 per share. All shares of CombiChem common stock issued pursuant to this Section 8.1 shall be deemed to be "Shares" within the meaning of the Stock Purchase Agreement.
Equity Purchase. Dainippon agrees to purchase $2,000,000 in equity of RiboGene. Such equity purchase shall be made on or before February 13, 1998, as the purchase of 756,144 shares of RiboGene's Series G Preferred Stock ("Series G Preferred") at a price per share of $2.645. The Series G Preferred shall have substantially the same terms and conditions and shall be accompanied by substantially the same investors rights as RiboGene's Series E Preferred stock purchased by its existing major collaboration partner. The Stock Purchase Agreement, Amended Articles of Incorporation and Investors Rights Agreement and forms of closing certificates and related documents shall be prepared and agreed by Dainippon and RiboGene not later than February 5, 1998.
